EUCTR2022-000886-42-HU进行中（未招募）1 期
A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years with Wheezing Lower Respiratory Illness
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- OM Pharma SA
- 入组人数
- 426
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Children of either gender aged between 6 months and 5 years, inclusive.
- •2. For children =1 year of age, =4 RTIs (as reported by parents or LAR of subject), including =2 episodes of wLRIs (including =1 triggering hospitalisation or medical visit) within 12 months prior to enrolment.
- •For children <1 year of age, =2 RTIs (as reported by parents or LAR of subject), including =1 episode of wLRIs (including =1 triggering hospitalisation or medical visit) within 6 months prior to enrolment.
- •3. Parents or LAR of subject have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 426
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Anatomic alterations of the respiratory tract.
- •2. Other respiratory chronic diseases (e.g., tuberculosis, cystic fibrosis).
- •3. Any autoimmune disease.
- •4. HIV infection or any type of congenital or iatrogenic immune deficiency (including IgA deficiency).
- •5. Congenital heart disease.
- •6. Haematologic diseases.
- •7. Liver or kidney failure.
- •8. New-borns before 34 weeks of gestational age.
- •9. Malnutrition as per World Health Organization (WHO) definition.
- •10. Any known neoplasia or malignancy.
- •11. Treatment with the following medications:
- •a. Systemic or oral steroids (e.g., oral prednisolone) within 4 weeks prior to study enrolment.
- •b. Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to study enrolment.
- •12. Previous use within last 6 months of enrolment or ongoing use of bacterial lysates.
- •13. Any major surgery within the last 3 months prior to study enrolment.
- •14. Known allergy or previous intolerance to investigational medicinal products (IMP).
- •15. Any other clinical conditions, that in the opinion of the Investigator, would not allow safe completion of the clinical study.
- •16. No other household members have previously been randomised in this clinical study.
- •17. Subjects’ families expected to relocate out of study area within 24 months of the initiation of the study.
- •18. Currently enrolled in or has completed any other investigational device or drug study or receiving other investigational agent(s) within <30 days prior to screening.
- •19. Parents or LAR who do not have access to internet connection.
研究者
相似试验
进行中（未招募）
1 期
OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory IllnessRespiratory Tract Infections with Wheezing Lower Respiratory IllnessMedDRA version: 20.0Level: HLGTClassification code 10024970Term: Respiratory tract infectionsSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-000886-42-PLOM Pharma SA426
招募中
1 期
OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory IllnessRespiratory Tract Infections with Wheezing Lower Respiratory IllnessMedDRA version: 20.0Level: HLGTClassification code: 10024970Term: Respiratory tract infections Class: 10038738CTIS2024-511581-37-00OM Pharma SA426
进行中（未招募）
1 期
A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects withUlcerative Colitis of the Rectum.lcerative Colitis of the RectumMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: HLTClassification code 10027682Term: Immune and associated conditions NECSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: HLGTClassification code 10027665Term: Immune disorders NECSystem Organ Class: 10021428 - Immune system disordersEUCTR2019-003596-19-ITCristcot HCA LLC618
招募中
1 期
A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum.EUCTR2019-003596-19-DKCristcot HCA LLC199
招募中
3 期
A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the RectumSubjects with Ulcerative Colitis of the RectumUlcerative Colitis of the RectumK51.2LBCTR2024015424Cristcot HCA LLC189